Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05413434
Other study ID # HacettepeKPR
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 1, 2022
Est. completion date April 1, 2023

Study information

Verified date August 2023
Source Hacettepe University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study will be conducted on individuals with Metabolic Syndrome. There are many studies showing that aerobic exercise provides significant improvements in waist circumference, fasting glucose, high-density lipoprotein cholesterol (HDL-C), Triglyceride (TG), systolic and diastolic blood pressure (SBP-DBP), and cardiorespiratory fitness on METS parameters. However, although the beneficial effects of physical activity are known, only half of the population adheres to the 150 minutes of moderate-intensity physical activity per week recommendation. High-intensity interval training (HIIT) is a type of training that uses near-maximal intensities in short-term sessions. HIIT has been used to improve compliance because it requires less time to treat patients with cardiometabolic disease. Compared to continuous aerobic exercise, this type of training has been shown to be an effective alternative for improving maximum oxygen consumption (VO2 max), blood pressure, heart function, glucose and lipid metabolism, and markers of oxidative stress and inflammation. In the literature, HIIT has been studied in patients with METS and has been shown to be effective. In addition, a study showed that seven-day respiratory muscle training was also effective on METS parameters, but there is no study showing the long-term effects of respiratory muscle training in this patient group. Therefore, in our study, researchers aimed to show the effects of respiratory muscle training given with HIIT on METS parameters.


Description:

Metabolic syndrome (METS) is a systemic endocrinopathy characterized by the presence of risk factors such as abdominal obesity, glucose intolerance or diabetes mellitus, atherogenic dyslipidemia, hypertension, and a persistent proinflammatory profile. According to the International Diabetes Federation (IDF) definition of METS, almost 20-25% of the adult world population has METS, and people with METS are at risk of heart attack, stroke, type 2 diabetes (T2D), all-cause and cardiovascular death (approximately three times higher). In addition, modifiable risk factors such as physical inactivity, diet, and sedentary behavior have all been associated with increased prevalence of METS. Increasing incidence of METS, increase in morbidity and mortality necessitated the implementation of preventive strategies and the implementation of pharmacological and non-pharmacological treatments. Studies in the literature have shown that vagal tone decreases and sympathetic tone increases in patients with METS. At the same time, impaired baroreflex sensitivity and decreased heart rate variability are observed in these patients. Changes in autonomic modulation cause the release of some bioactive molecules by affecting the endocrine and immune systems. In this case, increased sympathetic autonomic tone creates a cardiometabolic risk. In adults with METS, autonomic dysfunction appears to be more prominent in women than in men. Autonomic functions are impaired due to changes such as loss of lean body mass, increase in fat mass, increase in body mass, redistribution of fat from the periphery to the middle parts of the body, especially in postmenopausal women. As a result, increased blood pressure, impaired endothelial function, decreased glucose tolerance, and atherogenic changes in lipid and coagulation profiles can be observed. This increases the incidence of METS in postmenopausal women. Therefore, strategies to reduce the risk of metabolic syndrome have often been studied on women in the literature, and there is a need for studies involving men and new strategies. Physical activity and exercise training are recommended as key prescriptions for the prevention and treatment of METS and low-grade chronic inflammation . Increase in physical exercise has been recommended for the prevention and primary treatment of cardiovascular disease (CVD) and METS because of the cardioprotective benefits associated with improved cardiorespiratory fitness (CRF). There are many studies showing that aerobic exercise provides significant improvements in waist circumference, fasting glucose, high-density lipoprotein cholesterol (HDL-C), TG, systolic and diastolic blood pressure (SBP-DBP), and cardiorespiratory fitness on METS parameters . However, although the beneficial effects of physical activity are known, only half of the population adheres to the 150 minutes of moderate-intensity physical activity per week recommendation. It has been shown that one of the main barriers to reaping health benefits and being more active is "lack of time". High-intensity interval training (HIIT) is a type of training that uses near-maximal intensities in short-term sessions. HIIT has been used to improve compliance because it requires less time to treat patients with cardiometabolic disease. Compared to continuous aerobic exercise, this type of training is an effective alternative to improve maximum oxygen consumption (VO2max), blood pressure, heart function, glucose and lipid metabolism, and markers of oxidative stress and inflammation . However, it has been seen that there are not enough studies on HIIT effectiveness on METS parameters in the literature. Therefore, researchers aimed to show the effects of HIIT training applied together with respiratory muscle training on METS parameters in patients with METS. It has shown the beneficial effects of exercise training as well as inspiratory muscle training (IME) on autonomic function in patients with hypertension and heart disease . In a study, it was shown that 7-day inspiratory muscle training improved respiratory muscle functions and cardiac autonomic functions in postmenopausal women . As a result of this study, inspiratory muscle training has been proposed as a nonpharmacological strategy to improve autonomic modulation and reduce risk factors in individuals with METS, but further studies are required to confirm the long-term effects or effects of inspiratory muscle training in addition to classical exercise training protocols such as aerobic, resistance or combined training. are needed. In a study conducted in healthy and middle-aged men and postmenopausal women in 2021, it was proven that high resistance inspiratory muscle strength training can improve blood pressure control and vascular endothelial function, and reduce the risk of cardiovascular disease and other clinical disorders. In this study, researchers presented the first evidence that inspiratory muscle strength training increases NO bioavailability, decreases systemic inflammation, and causes potentially beneficial changes in the plasma metabolome by increasing endothelial NO synthase activation and decreasing oxidative stress. In conclusion, it has been shown that inspiratory muscle strength training can be used as a promising lifestyle intervention to improve cardiovascular function and reduce the risk of other clinical disorders . Since the long-term effects of respiratory muscle training in individuals with METS have not been examined in the literature; researchers planned this study to examine the effects of inspiratory muscle strength training added to aerobic exercise training (HIIT) on physical fitness, respiratory functions and METS parameters in individuals with METS.


Recruitment information / eligibility

Status Completed
Enrollment 38
Est. completion date April 1, 2023
Est. primary completion date March 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - METS will be defined according to the National Adult Cholesterol Education Program Adult Treatment Panel III. Patients with at least three or more of the following five characteristics will be included in the study: - Waist circumference =102 cm for men or =88 cm for women; - blood pressure above 130/85 mmHg; - Fasting blood glucose (FG) =100 mg/dL; - Blood TG =150 mg/dL; and - HDL-C < 40 mg/dL for men and < 50 mg/dL for women. - Not participating in any physical activity program (=2 physical activity days per week = 30 minutes per session). - 18 -65 years - to walk and cooperate - to participate in the research Exclusion Criteria: - heart failure, - pectoris, - of myocardial infarction or stroke in less than one year, - hypertension, - cardiovascular or kidney disease, - with peripheral vascular disease and any disease associated with exercise intolerance will be excluded.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
exercise
high-intensity interval training will be performed on the treadmill.
Device:
inspiratory muscle training
Respiratory muscle strength exercise will be performed with the respiratory muscle strengthening device 'POWERbreathe Classic Light Resistance'.

Locations

Country Name City State
Turkey Hacettepe University Ankara

Sponsors (1)

Lead Sponsor Collaborator
Hacettepe University

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary VO2max Cardiorespiratory fitness will be performed using a cardiopulmonary exercise test (CPET) with a treadmill, using the measurement method (breath by breath) with each breath. The modified Bruce protocol will be applied.VO2max will be recorded in ml/kg/min. 8 weeks
Secondary functional capacity Functional capacity will be evaluated with a 1 minute sit-stand test. The number of sit-ups will be noted. 8 weeks
Secondary flexibility flexibility will be evaluated with the functional reach test and sit and reach test. Results will be recorded in cm. 8 weeks
Secondary systolic and diastolic blood pressure Systolic and diastolic blood pressure will be measured using a digital sphygmomanometer (BP710, Omron, Tokyo, Japan) and results will be recorded in millimeters of mercury (mmHg). After the participants rest for 5 minutes in a sitting position, two measurements will be taken with an interval of 1 minute. The average of the two measurements will be recorded in mmHg. 8 weeks
Secondary C-Reactive Protein (CRP) Fasting blood samples will be taken from the patients before and after the 8-week training, after 12 hours of fasting, at Hacettepe University Hospital, Department of Internal Medicine, General Internal Medicine. It will be held in the morning, 48 hours after the end of the training. CRP will be recorded in mg/dl. 8 weeks
Secondary Low Density Lipoprotein Cholesterol (LDL-C) Fasting blood samples will be taken from the patients before and after the 8-week training, after 12 hours of fasting, at Hacettepe University Hospital, Department of Internal Medicine, General Internal Medicine. It will be held in the morning, 48 hours after the end of the training. LDL-C will be recorded in mg/dl. 8 weeks
Secondary High Density Lipoprotein Cholesterol (HDL-C) Fasting blood samples will be taken from the patients before and after the 8-week training, after 12 hours of fasting, at Hacettepe University Hospital, Department of Internal Medicine, General Internal Medicine. It will be held in the morning, 48 hours after the end of the training. HDL-C will be recorded in mg/dl. 8 weeks
Secondary Total Cholesterol Fasting blood samples will be taken from the patients before and after the 8-week training, after 12 hours of fasting, at Hacettepe University Hospital, Department of Internal Medicine, General Internal Medicine. It will be held in the morning, 48 hours after the end of the training. Total Cholesterol will be recorded in mg/dl. 8 weeks
Secondary Triglycerides(TC) Fasting blood samples will be taken from the patients before and after the 8-week training, after 12 hours of fasting, at Hacettepe University Hospital, Department of Internal Medicine, General Internal Medicine. It will be held in the morning, 48 hours after the end of the training. TC will be recorded in mg/dl. 8 weeks
Secondary Fasting blood glucose Fasting blood samples will be taken from the patients before and after the 8-week training, after 12 hours of fasting, at Hacettepe University Hospital, Department of Internal Medicine, General Internal Medicine. It will be held in the morning, 48 hours after the end of the training. Fasting blood glucose will be recorded in mg/dl. 8 weeks
Secondary Hemoglobin A1c(HbA1c) Fasting blood samples will be taken from the patients before and after the 8-week training, after 12 hours of fasting, at Hacettepe University Hospital, Department of Internal Medicine, General Internal Medicine. It will be held in the morning, 48 hours after the end of the training. HbA1c will be described in %. 8 weeks
Secondary spot urinalysis In the urine analysis, albumin, protein and creatinine values will be recorded as mg/dl. 8 weeks
Secondary height A non-flexible and sensitive up to 0.1 cm tape measure will be used to measure the height of the participants.Height will be recorded in centimeter(cm) . 8 weeks
Secondary body weight Body Composition Scale will be used for body composition measurement . Body weight will be recorded in kilogram(kg). 8 weeks
Secondary Body mass index(BMI) Weight and height will be combined to report BMI in kg/m^2. 8 weeks
Secondary Body fat ratio Body fat ratio will be measured with 'MI Scala 2'. It will be recorded in %. 8 weeks
Secondary Respiratory function Pulmonary function test parameters will be performed with a portable spirometer device in sitting position, taking into account the criteria of the American Thoracic Society and the European Respiratory Society. Forced Vital Capacity (FVC %), Forced expiratory volume (FEV1%) ,Peak expiratory flow (PEF %), forced mid-expiratory flow (FEF25-75%) will be recorded. 8 weeks
Secondary respiratory muscle strength Respiratory muscle strength will be evaluated with a portable intraoral pressure gauge ('Micro Medical( MicroRPM), Rochester, UK). Maximal inspiratory pressure and maximal expiratory pressure values will be recorded in centimeters of water(cmH2O). 8 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04635202 - Effect of Elliptical Training on Metabolic Homeostasis in Metabolic Syndrome N/A
Completed NCT04053686 - An Intervention to Reduce Prolonged Sitting in Police Staff N/A
Completed NCT05343858 - Pilot Study to Evaluate the Effect of Two Microalgae Consumption on Metabolic Syndrome N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Recruiting NCT05040958 - Carotid Atherosclerotic Plaque Load and Neck Circumference
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Active, not recruiting NCT02500147 - Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS) Phase 4
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Completed NCT03289897 - Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan N/A
Recruiting NCT05956886 - Sleep Chatbot Intervention for Emerging Black/African American Adults N/A
Completed NCT06057896 - Effects of Combined Natural Molecules on Metabolic Syndrome in Menopausal Women
Active, not recruiting NCT03613740 - Effect of Fucoxanthin on the Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion Phase 2
Completed NCT04498455 - Study of a Prebiotic Supplement to Mitigate Excessive Weight Gain Among Physicians in Residency Phase 4
Completed NCT05688917 - Green Coffee Effect on Metabolic Syndrome N/A
Completed NCT04117802 - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome N/A
Completed NCT03697382 - Effect of Daily Steps on Fat Metabolism N/A
Completed NCT03241121 - Study of Eating Patterns With a Smartphone App and the Effects of Time Restricted Feeding in the Metabolic Syndrome N/A
Completed NCT04509206 - Virtual Teaching Kitchen N/A
Completed NCT05124847 - TREating Pediatric Obesity N/A